Rasagiline

CAS No. 136236-51-6

Rasagiline( Azilect )

Catalog No. M11493 CAS No. 136236-51-6

Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 31 In Stock
25MG 50 In Stock
50MG 72 In Stock
100MG 95 In Stock
200MG 128 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Rasagiline
  • Note
    Research use only, not for human use.
  • Brief Description
    Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
  • Description
    Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.(In Vitro):Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment.(In Vivo):Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy.
  • In Vitro
    Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment. Cell Proliferation Assay Cell Line:Neuroblastoma SH-SY5Y, and glioblastoma 1242-MG Concentration:0.25 nM Incubation Time:96 hours Result:Caused ~60% increase in the cell proliferation rate for SH-SY5Y cells treated with Dexamethasone.Caused ~35% increase in cell proliferation rate for 1242-MG cells treated with Dexamethasone.
  • In Vivo
    Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy. Animal Model:(PLP)-α-synuclein transgenic mice over 6 months of age Dosage:Low-(0.8 mg/kg b.w.) and high dose (2.5 mg/kg b. w.) Administration:Administered subcutaneously every 24 h for a total period of 4 weeks (from day 1 till day 28 of the experiment). Result:Low dose treatment did not show protective efficacy in striatum with number of neurons similar to placebo treated MSA mice. High dose was associated with about 15% rescue of DARPP-32 immunoreactive striatal neurons.Low dose treatment had no effect on nigral neuronal loss, but high dose completely protected nigral neurons with numbers comparable to healthy controls.
  • Synonyms
    Azilect
  • Pathway
    Tyrosine Kinase
  • Target
    Bcr-Abl
  • Recptor
    Bcl-2| MAO-A| MAO-B
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    136236-51-6
  • Formula Weight
    171.24
  • Molecular Formula
    C12H13N
  • Purity
    >98% (HPLC)
  • Solubility
    Soluble in Water
  • SMILES
    C#CCN[C@@H]1CCc2c1cccc2
  • Chemical Name
    1-Indanamine, N-2-propynyl-, (R)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Naoi M, Maruyama W. Expert Rev NeurOthers. 2009 Aug;9(8):1233-50.
molnova catalog
related products
  • GNF-5

    GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).

  • Dasatinib monohydrat...

    Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML).

  • Precyasterone

    Precyasterone is a natural product isolated from the dried roots of?Cyathula capitata.